Fusion gene of ETV6-NTRK3 presence in hematological system malignant tumor and its clinical significance

Objective:To investigate the expression of the fusion gene of ETV6-NTRK3 and its feature in hematological malignagcy;explore the relationship between the fusion gene and its immunophenotype;evaluate its value in the clinical dignosis,therapy and prognosis.Method:Collect 47 samples which were untreated and 14 samples of AML-M2 which were therapied by two courses with standard chemotherapy regimen,to amplify specific fusion gene fragment by RT-PCR method,flow cytometry was applied to analyze the immunophenotype of the 47 samples.Result:Under the ultraviolet light,two samples expressed ETV6-NTRK3 fusion gene among 47 samples.The positive rate was 14% in AML-M2(2/14).We could not detect any reciprocal products of NTRK3-ETV6.A nomal NTRK3 message was also undetectable.Conclusion:①About 14% AML-M2 can express ETV6-NTRK3 fusion gene t(12;15)(p13;q25).All of them are AML-M2a.②The present standard therapic program can not take any effect on the patients with ETV6-NTRK3 fusion gene;which is refractory leukemia,so the prognosis is badly.③According to the FCM immunophenotype analysis,the patients with ETV6-NTRK3 fusion gene expressed CD13 and CD33,and the expression of CD13 is stronger than that of CD33.No-CD14 expression.It signified the leukemic cell of the patients originated early,differentiated badly,and was high-grade malignancy.